



January 18, 2024

To Whom This May Concern:

On January 24, 2023, Catalyst Pharmaceuticals, Inc. ("Catalyst") acquired the U.S. rights for Fycompa (perampanel) from Eisai Inc. As of that date, Catalyst assumed the authority to set pricing for Fycompa, including the NDCs set out in the table below. Catalyst is also responsible for applicable state price reporting responsibilities associated with Fycompa as of January 24, 2023. We send this communication to provide you notice of this change to help avoid confusion.

Please note, the NDCs below include an Eisai Labeler Code because Eisai is still responsible for manufacturing and distributing Fycompa. Eisai expects Catalyst will have the capacity to manufacturer and distribute Fycompa by Q1 2024, at which time the NDCs will include a Catalyst Labeler Code.

PRODUCT DESCRIPTION	PACK SIZE	NDC
Fycompa (perampanel)	2mg X 30 Tablets	62856-0272-30
Fycompa (perampanel)	4mg X 30 Tablets	62856-0274-30
Fycompa (perampanel)	6mg X 30 Tablets	62856-0276-30
Fycompa (perampanel)	8mg X 30 Tablets	62856-0278-30
Fycompa (perampanel)	10mg X 30 Tablets	62856-0280-30
Fycompa (perampanel)	12mg X 30 Tablets	62856-0282-30
Fycompa OS (perampanel)	0.5mg/ml X 340ml, Oral Suspension	62856-0290-38

Should you have any questions or need additional information, please contact Maria Pandolfo of Catalyst Pharmaceutical, Inc. at (847) 778-7715 or Gary Smith of Eisai at (201) 874-9334.

Sincerely,

Gary Smith
Senior Director, Pricing and Contracting
Eisai Inc.